X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
alemtuzumab (478) 478
humans (460) 460
hematology (356) 356
transplantation (306) 306
male (304) 304
index medicus (294) 294
female (289) 289
adult (262) 262
antibodies, monoclonal, humanized (242) 242
middle aged (239) 239
immunology (204) 204
oncology (185) 185
bone-marrow-transplantation (166) 166
transplantation, homologous (162) 162
antibodies, monoclonal - therapeutic use (157) 157
transplantation conditioning - methods (150) 150
stem cells (147) 147
treatment outcome (143) 143
versus-host-disease (140) 140
adolescent (135) 135
antibodies, neoplasm - therapeutic use (133) 133
hematopoietic stem cells (131) 131
graft vs host disease - prevention & control (126) 126
aged (125) 125
stem-cell transplantation (125) 125
hematopoietic stem cell transplantation (107) 107
hematopoietic stem cell transplantation - methods (98) 98
child (96) 96
retrospective studies (96) 96
vidarabine - analogs & derivatives (93) 93
hematopoietic stem cell transplantation - adverse effects (90) 90
hematology, oncology and palliative medicine (86) 86
antineoplastic agents - therapeutic use (83) 83
young adult (81) 81
child, preschool (77) 77
health aspects (76) 76
antibodies, monoclonal - administration & dosage (74) 74
transplantation conditioning (73) 73
antibodies, neoplasm - administration & dosage (71) 71
care and treatment (71) 71
immunosuppressive agents - therapeutic use (71) 71
campath-1h (68) 68
stem cell transplantation (68) 68
leukemia (67) 67
risk factors (67) 67
antibodies, monoclonal, humanized - therapeutic use (65) 65
fludarabine (65) 65
t cells (64) 64
graft vs host disease - etiology (61) 61
survival analysis (58) 58
research (57) 57
therapy (56) 56
disease-free survival (55) 55
unrelated donors (54) 54
follow-up studies (53) 53
infant (53) 53
recurrence (53) 53
vidarabine - administration & dosage (51) 51
antineoplastic combined chemotherapy protocols - therapeutic use (50) 50
children (50) 50
immune reconstitution (50) 50
antibodies, monoclonal - adverse effects (49) 49
survival (49) 49
transplantation chimera (48) 48
antineoplastic agents - administration & dosage (47) 47
monoclonal antibodies (47) 47
t-lymphocytes - immunology (47) 47
analysis (46) 46
survival rate (45) 45
hematologic neoplasms - therapy (44) 44
immunotherapy (44) 44
antibodies, neoplasm - adverse effects (43) 43
cd52 antigen (43) 43
mortality (43) 43
bone marrow transplantation (42) 42
graft vs host disease - drug therapy (42) 42
lymphocyte depletion (42) 42
rituximab (42) 42
allogeneic transplantation (41) 41
antibodies, monoclonal, humanized - administration & dosage (41) 41
graft vs host disease - immunology (41) 41
recipients (41) 41
transplantation conditioning - adverse effects (41) 41
acute myeloid-leukemia (40) 40
chemotherapy (40) 40
vidarabine - therapeutic use (40) 40
bone marrow (39) 39
disease (38) 38
antithymocyte globulin (37) 37
chronic lymphocytic-leukemia (37) 37
chimerism (36) 36
cyclophosphamide (36) 36
graft survival (36) 36
graft vs host disease - mortality (36) 36
reduced-intensity conditioning (36) 36
graft-versus-host disease (35) 35
leukemia, lymphocytic, chronic, b-cell - drug therapy (35) 35
patient outcomes (35) 35
pediatrics (35) 35
antibodies, monoclonal - pharmacology (34) 34
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 01/2011, Volume 46, Issue 1, pp. 143 - 147
The efficacy and safety of CD52 antibody alemtuzumab to treat severe acute GVHD in 18 consecutive patients refractory to standard high-dose corticosteroid... 
acute GVHD | allogeneic stem cell transplantation | alemtuzumab/Campath-1H | antibody therapy | CAMPATH-1H | ONCOLOGY | IMMUNOLOGY | HEMATOLOGY | VERSUS-HOST-DISEASE | ANTI-CD52 MONOCLONAL-ANTIBODY | TRANSPLANTATION | Antibodies, Neoplasm - therapeutic use | Graft vs Host Disease - complications | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal - adverse effects | Glycoproteins - metabolism | Antibodies, Monoclonal - therapeutic use | Adrenal Cortex Hormones - therapeutic use | Virus Diseases - complications | Graft vs Host Disease - immunology | Leukemia, Myeloid, Acute - complications | Antigens, CD - metabolism | Young Adult | Antibodies, Monoclonal, Humanized | Bacterial Infections - complications | Gastrointestinal Diseases - drug therapy | Hematopoietic Stem Cell Transplantation - adverse effects | Antigens, Neoplasm - metabolism | Liver Diseases - complications | Adult | Gastrointestinal Diseases - immunology | Immunosuppressive Agents - administration & dosage | Leukemia, Myeloid, Acute - therapy | CD52 Antigen | Liver Diseases - immunology | Gastrointestinal Diseases - complications | Treatment Outcome | Alemtuzumab | Antibodies, Neoplasm - administration & dosage | Lymphocyte Depletion - adverse effects | Graft vs Host Disease - drug therapy | Antibodies, Monoclonal - administration & dosage | Adolescent | Survival Analysis | Immunosuppressive Agents - adverse effects | Aged | Liver Diseases - drug therapy | Antibodies, Neoplasm - adverse effects | Physiological aspects | Graft versus host reaction | Care and treatment | Transplantation | Patient outcomes | Stem cells
Journal Article
Blood, ISSN 0006-4971, 10/2010, Volume 116, Issue 16, pp. 3080 - 3088
Journal Article
Blood, ISSN 0006-4971, 01/2004, Volume 103, Issue 2, pp. 428 - 434
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2009, Volume 15, Issue 6, pp. 671 - 678
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2016, Volume 22, Issue 12, pp. 2220 - 2225
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2009, Volume 15, Issue 5, pp. 610 - 617
Abstract The purpose of this study was to determine the effect of alemtuzumab on treatment-related mortality (TRM), relapse, overall survival (OS), and... 
Hematology, Oncology and Palliative Medicine | AML | T cell depletion | Allogeneic transplant | Alemtuzumab | MDS | BONE-MARROW-TRANSPLANTATION | ACUTE MYELOGENOUS LEUKEMIA | PREPARATIVE REGIMENS | UNRELATED DONOR TRANSPLANTATION | ACUTE MYELOID-LEUKEMIA | IMMUNOLOGY | VERSUS-HOST-DISEASE | MYELODYSPLASTIC SYNDROME | TRANSPLANTATION | INTENSITY ALLOGENEIC TRANSPLANTATION | STEM-CELL TRANSPLANTATION | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Antibodies, Neoplasm - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Melphalan - therapeutic use | Hematopoietic Stem Cell Transplantation - mortality | Transplantation Conditioning - mortality | Young Adult | Antibodies, Monoclonal, Humanized | Myelodysplastic Syndromes - therapy | Antibodies, Neoplasm - pharmacology | Vidarabine Phosphate - analogs & derivatives | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Transplantation Conditioning - adverse effects | Transplantation Conditioning - methods | Vidarabine Phosphate - therapeutic use | Child | Leukemia, Myeloid, Acute - therapy | Antibodies, Monoclonal - pharmacology | Treatment Outcome | Myelodysplastic Syndromes - complications | Adolescent | Myelodysplastic Syndromes - mortality | Graft vs Host Disease - prevention & control | Aged | Hematopoietic Stem Cell Transplantation - methods
Journal Article
Journal Article
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2009, Volume 15, Issue 12, pp. 1563 - 1570
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 07/2008, Volume 42, Issue 1, pp. 51 - 56
Journal Article
Bone Marrow Transplantation, ISSN 0268-3369, 05/2009, Volume 43, Issue 9, pp. 709 - 715